Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SIBP-04 vs Bevacizumab in Healthy Males
NCT04135898Phase 1Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SIBP-04 in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration. Started Oct 2019; status: completed.
02
Drugs
SIBP-04
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04135898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135898.